Dual blockade of the renin angiotensin system in diabetes - Rationale and risks

British Journal of Diabetes and Vascular Disease

Volumn 5, Issue 5, 2005, Pages 266-271

  Kumar, Rajeev ^a   Winocour, Peter H ^b  

^a QUEEN ELIZABETH II HOSPITAL   (United Kingdom)

^b NONE

Author keywords

Diabetes mellitus; Dual blockade; Hyperkalaemia; Renin angiotensin system

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CHOLESTEROL; CILAZAPRIL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LISINOPRIL; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; POTASSIUM; RENIN; SPIRONOLACTONE; VALSARTAN;

ACUTE KIDNEY FAILURE; ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DEVELOPED COUNTRY; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; HEART FAILURE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERKALEMIA; HYPERTENSION; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DYSFUNCTION; KIDNEY FAILURE; MICROALBUMINURIA; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 28444442015     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514050050050501     Document Type: Review

References (44)

1. Ritz E, Rychlik I, Locatalli F, Halami S. End stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999;34:795-808.
2. Laakso M. Hyperglycaemia and cardiovascular disease in type 2 diabetes. Diabetes 1999;48:937-42.
3. United Kingdom Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. UKPDS 33. Lancet 1998;352:837-53.
4. United Kingdom Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ;317:703-13.
5. Angélique ME, Spoelstra-de Man, Catherine B et al. Rapid Progression of Albumin Excretion Is an Independent Predictor of Cardiovascular Mortality in Patients With Type 2 Diabetes and Microalbuminuria. Diabetes Care 2001;24:2097-101.
6. Parving H-H, Østerby R, Ritz E. Diabetic nephropathy. In: Brenner BM, Levine S, Eds. The Kidney 6th edition. Philadelphia, WB Saunders, 2000; 1731-73.
7. Williams B, Poulter N, Brown M et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004; 328:634-40.
8. Rosner MH, Okusa MD. Combination therapy with angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists in the treatment of patients with type 2 diabetes mellitus. Arch Intern Med 2003; 163:1025-9.
9. Tomlinson JW, Owen K, Close CF. Treating hypertension in diabetic nephropathy. Diabetes Care 2003;26:1802-05.
10. Winocour PH. Effective diabetes care: a need for realistic targets. BMJ 2002;324:1577-80.
11. Elliott WJ. Therapeutic trials comparing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers. Curr Hypertens Rep 2000; 2:402-11.
12. Lewis EJ, Hunsicker LG, Bain RP et al. for The Collaborative Study Group. The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic Nephropathy. N Engl J Med 1993;329;1456-62.
13. Ravid M, Lang R, Rachmani R et al. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7 year follow-up study. Arch Intern Med 1996;156:286-9.
14. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.
15. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
16. Rossing P, Hommel E, Smidt UM et al. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 1994;37: 511-16.
17. American Diabetes Association: clinical practice recommendation 2004. Diabetes Care 2004;27(suppl 1):S1-S150.
18. Gerstein HC, Yusuf S, Mann JFE et al. for the Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE sub study. Lancet 2000;355;253-9.
19. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995;273:1450-6.
20. Cohn JN, Tognoni G, for the Val-HeFT Investigators. Effects of the angiotensin receptor blocker valsartan on morbidity and mortality in heart failure: The Valsartan Heart Failure Trial (Val-HeFT). Circulation 2000;267:2672-6.
21. Dahlöf B, Devereux RB, Kjeldsen SE et al. for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
22. Pfeffer MA, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759-66.
23. van den Meiracker AH, Man in 't Veld AJ, Admiraal PJ et al. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? J Hypertens 1992;10:803-12.
24. Balcells E, Meng QC, Johnson WH Jr et al. Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol 1997;273:H1769-H1774.
25. Ohishi M, Ueda M, Rakugi H et al. Upregulation of angiotensin-converting enzyme during the healing process after injury at the site of percutaneous transluminal coronary angioplasty in humans. Circulation 1997; 96:3328-37.
26. Cao Z, Bonnet F, Candido R et al. Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury. J Am Soc Nephrol 2002;13:1773-87.
27. 1 receptor function and density in hypercholesterolemic men. Circulation 1999;100:2131-4.
28. Mogensen CE, Neldam S, Tikkanen I et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321:1440-4.
29. Jacobsen P, Andersen S, Rossing K et al. Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. Nephrol Dial Transplant 2002;17:1019-24.
30. Jacobsen P, Andersen S, Rossing K et al. Dual blockade of the renin-angiotensin system versus maximal recommended doses of ACE inhibition in diabetic nephropathy. Kidney International 2003;63:1874-80.
31. Rossing K, Jacobson F, Pietraszek L et al. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: A randomized double-blind crossover trial. Diabetes Care 2003;26:2268-74.
32. Rossing K, Christensen PK, Parving HH. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care 2002;25:95-100.
33. Andersen NH, Poulsen FL, Knudsen ST et al. Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: The CALM II study. Diabetes Care 2005;28:273-7.
34. Palmer BF. Managing hyperkalaemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2004;351:585-92.
35. Ahuja TS, Freeman D, Mahnken JD et al. Fredictors of the development of hyperkalemia in patients using angiotensin-converting enzyme inhibitors. Am J Nephrol 2000;20:268-73.
36. Reardon LC, Macpherson DS. Hyperkalaemia in outpatients using angiotensin converting enzyme inhibitors. Arch Int Med 1998;158;26-32.
37. Nicholls AJ. The impact of atherosclerotic renovascular disease on diabetic renal failure. Diabet Med 2002;19:889-4.
38. Bonnet F, Thivole CH. Reversible hyperkalemia at the initiation of ACE inhibitors in a young diabetic patient with latent hyporeninemic hypoaldosteronism (letter). Diabetes Care 1996;19:81.
39. Ruilope LM, Aldigier JC, Ponticelli C et al. on behalf of the European Group for the Investigation of Valsartan in Chronic Renal Disease. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. J Hypertension 2000;18:89-95.
40. Struthers AD. Aldosterone: cardiovascular assault. Am Heart J 2002; 144:S2-S7.
41. Rachmani R, Slavachevsky I, Amit M et al. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomised controlled study. Diabet Med 2004;21:471-5.
42. Sato A, Hayashi K, Naruse M et al. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003;41:64-8.
43. Krum H, Nolly H, Workman D et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002; 40:117-23.
44. Epstein M, Buckalew V, Altamirano J et al. Eplerenone reduces proteinuria in type II diabetes mellitus: implications for aldosterone involvement in the pathogenesis of renal dysfunction. J Am Coll Cardiol 2002; 39(suppl A):249A.Abstract.